Xtent Aims For Long-Lesion Indication For Its Custom NX Drug-Eluting Stent

Buoyed by recent European clinical trial results, drug-eluting stent developer Xtent expects to begin a U.S. pivotal trial later this year in support of an indication no other drug-eluting coronary stent company has: treatment of long lesions and multiple lesions